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Abstract 
Neutrophil recruitment to the site of acute inflammation is a multistep process regulated 
by specific signaling molecules. The signaling mechanisms that regulate neutrophil-
endothelial cell interactions remain incompletely understood. p38 mitogen-activated 
protein kinase (MAPK) signalling was shown to regulate different steps of neutrophil 
migration in response to inflammatory stimuli. The mitogen- and stress-activated protein 
kinase-1 (MSK1) can be activated by either extracellular-signal-regulated kinase (ERK) 1/2 
or p38 MAPK. The aim of the present study is to investigate the effects of pharmacological 
suppression of MSK1 by its specific inhibitor, SB747651A, on various steps of neutrophil 
recruitment. In vivo studies were conducted using real-time and time-lapsed intravital 
video microscopy of the cremaster microcirculation to determine the dynamic leukocyte-
endothelial cell interactions. Intrascrotal injection of macrophage inflammatory protein-2 
(MIP-2, 0.2 µg/mouse) decreased leukocyte rolling velocity which was significantly 
reversed by pre-treatment with SB747651A (intrascrotal injection of 3 mg/kg). SB747651A 
pre-treatment enhanced MIP-2-induced increase in neutrophil adhesion and emigration. 
To better understand the effect of SB747651A on different steps of neutrophil 
recruitment, we placed a small piece of MIP-2-containing agarose gel on the exposed 
cremaster muscle and studied directed migration of neutrophils in the postcapillary 
venule and in the tissue. Superfusion of SB747651A (5 µM) on cremaster muscle 
subjected to MIP-2 gradient significantly increased rolling velocity and adhesion, but 
decreased emigration of neutrophils in comparison to superfusion of normal saline 
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without SB747651A. SB747651A treatment significantly affected transmigration time, 
detachment time, intravascular crawling and the velocity of migration, but not the 
directionality of migrating neutrophils in tissue. The expression of intercellular adhesion 
molecule-1 (ICAM-1) in cultured endothelial cells was up-regulated by co-treatment with 
SB747651A and MIP-2 but not by MIP-2 alone. Flow cytometry analysis showed that co-
treatment of bone marrow neutrophils with SB747651A and MIP-2 significantly decreased 
macrophage antigen-1 (Mac-1) but not lymphocyte function associated antigen-1 (LFA-1) 
expression as compared with MIP-2 treatment alone. Collectively, our findings 
demonstrate that pharmacological suppression of MSK1 by SB747651A affects multiple 
steps of MIP-2-induced neutrophil recruitment in vivo.  
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Introduction 
1.   Inflammation 
Inflammation is a complex and defensive immune response which is normally under 
physiological regulation. It is characterized by the recruitment of leukocytes from blood 
to affected tissue in order to remove pathogens and start the process of repair in 
inflamed tissue (1). Inflammation can be divided into acute and chronic phases. Acute 
inflammation has a rapid onset and short duration, and is characterized by increased 
blood flow and vascular permeability along with  the extravasation of plasma proteins 
and fluids, production of inflammatory mediators such as cytokines and emigration of 
leukocytes, especially neutrophils at the postcapillary venules into the injured or 
infected area (2-5). Acute inflammation is a defensive mechanism that aims to kill  and  
to remove the infectious or injurious agents while still facilitating the resolution of the 
injured area. If the infectious or injurious agent is not eliminated during the acute phase 
of inflammation, the inflammation is prolonged and turns to chronic phase which 
manifests histologically by the existence of macrophages and lymphocytes, resulting in 
tissue damage and fibrosis (5).  
Inflammation is a delicate immune response that is tightly regulated by our body, but 
abnormalities of inflammation cause many human diseases, for example, asthma and 
contact dermatitis which result from hyperreactive immune response to allergens. 
Defective immune system makes the individual more susceptible to infections (e.g., 
leukocute adhesion deficiency disease (LADD) which is due to the absence of the β2 
integrin molecule on the surface of neutrophils called CD18 which plays an important 
2 
 
role in adhesion-dependent migration of neutrophils to the acute inflammation site) (6). 
Also, the persistent chronic inflammation causes many degenerative diseases such as 
atherosclerosis, rheumatoid arthritis (5). Uncontrolled inflammation causes many 
diseases that impairs the normal functions and life of the person. Therefore, it is very 
important to study the inflammation and mechanisms that are involved in its regulation. 
2. Leukocyte recruitment 
2.1 Neutrophil recruitment during inflammatory response  
The recruitment of neutrophils from the blood flow to the affected site (infection or 
injury) is the fundamental feature of inflammation. This recruitment takes place in the 
post-capillary venules of the inflamed tissue. It can lead to the removal of a causative 
pathogen but can also cause inappropriate dysfunction of the tissue (8). The changes on 
the venular endothelial surface initiating neutrophil recruitment, are caused by the 
stimulation of inflammatory agents or mediators (including cysteinyl leukotrienes, 
histamine and cytokines) which are secreted from resident leukocytes or other tissue 
cells in the affected tissue when they are stimulated by invading pathogens (7). At post-
capillary venules, there is a complicated process of cellular interactions  triggered 
between neutrophils and endothelial cells during neutrophil recruitment to the site of 
inflammation. The cascade of neutrophil recruitment includes the following sequential 
steps in most tissues: neutrophils tethering and rolling, adhesion, intraluminal crawling 
on the luminal surface of the post-capillary venules, transendothelial migration across 
the venule and finally directional migration in extra-vascular tissue to reach the affected 
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site (injury or infection) under the control and guidance of a chemotactic gradient 
(chemotaxis) (7-12). The process of neutrophil recruitment is regulated by many 
molecules such as selectins, integrins, chemokines and chemokine receptors. Figure 1 
presents a brief and schematic view of neutrophil recruitment cascade.  
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Figure 1. Neutrophil recruitment cascade. During  inflammation, neutrophils in the 
blood vessels tether and roll along the endothelial surface, and then adhere to 
endothelium firmly. After that, neutrophils crawl to the sites of transmigration which 
can be either paracellular (between endothelial cells; a) or transcellular (through 
endothelial cells; b) (modified from Reference 7).           
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2.1.1 Neutrophil tethering, rolling and adhesion 
Neutrophil tethering is the initial contact of neutrophils with the vascular endothelium 
and rolling is the following rotational movement along the endothelium. Neutrophil 
rolling  is mediated by specific cell adhesion molecules called selectins. These  selectins 
are one family of adhesion molecules belonging to calcium-dependent type I 
transmembrane glycoproteins (13,14). These selectins that mediate rolling of 
neutrophils are P-selectin, L-selectin, and E-selectin which are called by these names 
according to the type of tissues in which they were first discovered (platelet, leukocytes 
and endothelium, respectively) (13,14). The expression of P-selectin occurs 
constitutively in tissues and it is stored in secretory granules which are called Weibel-
Palade bodies in endothelium or α-granules in platelets. Once endothelium is activated 
by inflammatory stimuli such as leukotrienes, thrombin and histamine, the Weibel-
Palade bodies rapidly mobilize and merge with cell membrane resulting in the increased 
expression of P-selectins within minutes on the endothelial surface (21). In addition, P-
selectins can be synthesized by the endothelial cells upon stimulation of cytokines and 
this type of P-selectin up-regulation involves protein synthesis and the process is slower 
(usually from > 30 min to several hours ) (13,14). The up-regulation of the expression of 
E-selectins is through de novo protein synthesis in endothelium. When endothelial cells 
are activated by inflammatory mediators such as tumor necrosis factor-α (TNF-α), 
lipopolysaccharide (LPS) and interleukin-1 (IL-1), they express E-selectins on their 
surfaces. The expression of E-selctin on endothelium occurs within 2 hours after 
stimulation and declines in 24 hours. L-selectin was identified as the homing molecule 
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which allows lymphocytes to enter lymphoid tissues. L-selectin is expressed by most 
leukocytes (13-16,21). Leukocyte rolling is mediated by the interaction between 
selectins and P-selectin glycoprotein ligand 1 (PSGL1). It can also be mediated by other 
glycosylated ligands but PSGL1 is the dominant  ligand for all these three selectins. 
PSGL1 is expressed by all leukocytes and by certain endothelial cells (11,18,19). E-
selectins have other ligands which are E-selectin ligand 1, CD43, CD44 and L-selectin 
(11,13). Furthermore, it has been reported that some integrins are also involved in 
rolling step such as β2-integrin lymphocyte function-associated antigen-1 (LFA-1, 
CD11a/CD18, αLβ2 integrin) and α4-integrin very late antigen-4 (VLA4, α4β1 integrin) (20). 
Rolling of neutrophils on endothelium facilitates their contact with chemokines or other 
chemoattractants on the endothelial surface.   
The subsequent event is neutrophil adhesion. Triggering neutrophil arrest during rolling 
is mediated by chemoattractants and chemokines that are presented on the luminal 
surface of the endothelium (7). Neutrophil adhesion is mediated by the interaction of 
integrins on their surface with endothelial adhesion molecules in the family of 
immunoglobulin molecules such as intercellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) (11). The most relevant leukocyte integrins 
that mediate leukocyte arrest and adhesion are β2-integrins LFA-1 (CD11a/CD18, αLβ2 
integrin) and macrophage antigen-1 (Mac-1, CD11b/CD18, αMβ2 integrin) and the β1-
integrin VLA4 (α4β1 integrin) (11). Both  LFA-1 and Mac-1 mediate neutrophil adhesion 
but  it has been reported that LFA-1 (αLβ2 integrin) plays a dominant role in neutrophil 
adhesion step whereas Mac-1 (αMβ2 integrin) plays a more important role in the 
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subsequent crawling step (17). Endothelial ligand for LFA-1 is ICAM-1 and ICAM-2. Mac-
1 binds to ICAM-1 and to other ligands such as fibrinogen, fibronectin and complement 
fragment. VCAM-1 is the main endothelial ligand for α4β1-integrin VLA4 (13). VLA4-
VCAM-1 interaction mediates the rolling and adhesion of mononuclear leukocytes 
(monocytes and lymphocytes) and eosinophils. There are a few studies showing that this 
α4β1-integrin, in addition to its support for neutrophil rolling, also mediates and 
enhances neutrophil adhesion (13,20,117,118).  
Furthermore, shear flow is another crucial factor to initiate and to promote firm 
adhesion as it causes triggering and activation of β2-integrins through E-selectin 
signaling (21,22). 
 
2.1.2 Neutrophil intraluminal crawling  
The following newly identified step in neutrophil recruitment cascade is called 
intraluminal crawling. Intraluminal crawling means that the adherent leukocytes move 
from their initial adhesion site to the junctional extravasation site on the luminal surface 
of endothelium in response to chemokines in inflammation site (17,23). Schenkel et al. 
demonstrated that monocytes crawl from a site of firm adhesion to the nearest 
endothelial junction to transmigrate and this process was called locomotion. They found 
that blocking adhesion molecules such as β2 integrins (LFA-1 and Mac-1) on monocytes 
and their integrin ligands on endothelium (ICAM-1 and ICAM-2) prevented monocytes 
from reaching transmigration site (24). Neutrophils in inflamed postcapillary venules 
8 
 
also crawl after adhesion to reach the optimal transmigration sites. Phillipson et al. 
demonstrated that in LFA-1-deficient mice few neutrophils adhered in response to 
chemokines but surprisingly, the few number of LFA-1-deficient neutrophils that 
adhered were able to crawl as efficiently as neutrophils from wild-type mice. In 
contrast, neutrophils with Mac-1-deficiency were able to adhere efficiently but showed 
a dramatical decrease in intraluminal crawling compared to wild-type neutrophils in 
response to endogenous or exogenous chemokines. They also discovered that inhibition 
of ICAM-1 but not ICAM-2 impaired intraluminal crawling. Phillipson et al. concluded 
that ICAM-1 but not ICAM-2 mediates Mac-1-dependent crawling, and they also 
concluded that the neutrophil adhesion is mainly dependent on  LFA-1, the subsequent 
crawling step is mainly dependent on Mac-1 and, therefore, both LFA-1 and Mac-1 are 
important molecules for efficient neutrophil emigration out of blood vessel (17).   
2.1.3 Neutrophil transendothelial migration 
The subsequent fundamental step is the transmigration through the vascular wall that 
enables the leukocytes to leave the vasculature and move along chemoattractant 
gradiant in inflamed tissue (7). The leukocyte during its transmigtation through the 
vascular wall faces three different layers which are endothelial cells, the endothelial 
basement membrane and pericytes subsequently. The emigration of leukocytes  
through the layer of endothelial cell is fast  (<2-5 minutes), but they spend much longer 
time to  penetrate basement membrane of endothelial cell (>5-15 minutes) (11). 
Leukocytes transendothelial migration occurs either through endothelial junctions, 
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where the leukocytes pass between the adjacent endothelial cells and this is called 
paracellular transmigration route, or directly through the endothelial cells and this is 
called transcellular transmigration route (25,26). The factors determining which route is 
preferred are still unkown, but the route of transmigration may differ between different 
organs, different inflammatory stimuli and different types of emigrating leukocyte (25). 
The paracellular transmigration is the main route taken by neutrophils, as it has been 
reported that about 90% of neutrophil transmigration  occurs paracellularly (17,27-31). 
However, transcellular pathway is also used by emigrating neutrophils but it is less 
efficient because it takes longer time (20-30 minutes) (7,25). Since all adherent 
neutrophils crawl in Mac-1-dependent mechanism to reach to their optimal sites of 
transmigration which are thought to be at the endothelial junctions, Mac-1-deficient 
neutrophils transmigrate predominantly transcellularly in comparison to wild-type 
neutrophils that predominantly use the paracellular route (17). Transmigration process 
is mediated by integrins (VLA4, LFA-1 and Mac-1), immunoglobulin family cell adhesion 
molecules (VCAM-1, ICAM-1 and ICAM-2) and a variety of junctional proteins such as 
junctional adhesion molecules (JAMs), platelet/endothelial cell adhesion molecule-1 
(PECAM-1, CD31), epithelial cell adhesion molecule (ECAM),  CD99, leukocyte-specific 
protein-1 (LSP-1) and vascular adhesion protein-1 (VAP-1) (7,10,11,32).   
The paracellular migration of leukocytes occurs at endothelial cell junctions. During the 
paracellular migration, the vascular endothelial cadherin (VE-cadherin) is released to 
facilitate neutrophil tansmigration through endothelial junctions and it is enhanced by 
endothelial-cell junctional molecules such as PECAM-1, JAM-A, ESAM, ICAM-1/2 and 
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CD99. Neutrophil paracellular migration is also mediated by increased levels of 
intracellular endothelial calcium which triggers endothelial cells contraction through 
activation of myosin light-chain kinase. The contraction of endothelial cells causes 
widening of endothelial junctions and facilitates neutrophil paracellular transmigration 
(11). At the thin parts of endothelial cell-lining, the transcellular migration occurs, 
therefore neutrophils  cross less distance. Ligation of ICAM-1 stimulates cytoplasmic 
signaling events that cause transportation of apical ICAM-1 to F-actin- and caveolae-rich 
parts and subsequently transportation of ICAM-1 with caveolin-1 to the basal part of 
plasma membrane. All these events will lead to formation  of channels inside 
endothelial cell called vesiculo-vacuolar organelles (VVOs) through which the 
neutrophils migrate (11). During the transcellular migration, endothelial cells extend 
projections that moves up forming cup-like structure around the adherent leukocytes. 
The endothelial projections that form  dome-like structures (transmigratory cups) are 
rich in ICAM-1 and VCAM-1 that bind to LFA-1 and VLA4 on leukocyte surface (7,25). 
Figure 2 demonstrates the paracellular and transcellular routes of neutrophil 
transendothelial migration.    
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Figure 2. Transmigration pathways of neutrophils through the vascular routes. (A) 
Paracellular migration  occurs at endothelial cell junctions. (B) Transcellular migration 
occurs through endothelial cells (modified from Reference 11).   
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2.1.4 Neutrophil chemotaxis in tissue 
The capacity of a cell to sense the gradient of extracellular chemical signals 
(chemoattractant) and respond by  directional migration towards their sources is a vital 
cellular mobile process  called chemotaxis (33).       
 After neutrophils cross the vascular wall and reach the extra-vascular tissue, they start 
directional movement toward the chemoattractant source at the injury or infection site. 
Neutrophil chemotaxis is a dynamic process that involves a combination of directional 
sensing, cell polarization, cell adhesion and motility (34-37). Neutrophils have an 
extraordinary ability to detect and respond to very low chemoattractant gradient (as 
low as 2% difference across their length) (33,39,40). They perform this function through 
their ability to amplify the chemotactic gradient signals via conversion of small changes 
in the extracellular chemoattractant concentration into highly polarized intracellular 
signaling events through activation of many downstream signal transduction pathways 
which lead to dramatic redistribution of cytoskeletal components that ultimately lead to 
directed migration (33). Sensing of chemotactic stimuli is mediated by the stimulation 
and activation of G protein-coupled receptors (GPCRs) on the surface of neutrophils 
during binding of chemoattractants to GPCRs (23).  Once GPCRs are activated, they 
transmit the signals to many downstream signaling pathways causing cell polarization 
and morphological changes in neutrophils to enable them to migrate towards the 
chemoattractant gradient. The cell fronts (leading edge) of the polarized neutrophils 
have constantly protruding and retracting motile membranous structures which are 
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called lamellipodia or filopodia. These filopodia are consistently oriented in the direction 
of chemotaxis. The rear of the cell (trailing edge or tail) is termed uropod (41). 
Neutrophil polarization is mediated  by significant redistribution of cytoskeletal 
elements. It involves localization of F-actin and many actin binding proteins at the 
leading edge (the front of the cell) and localization of myosin II and actin filaments at 
the back (trailing edge) and at the sides of polarized neutrophils (42). This structural 
front-rear polarization is required for efficient tanslocation and movement of 
neutrophils toward chemokine gradient (41).  
When chemoattractants bind to transmembrane GPCRs, several signaling pathways are 
activated to mediate neutrophil cell polarization and to enhance chemotaxis process 
towards chemoattractant stimuli that might be endogenous stimuli (IL-8, LTB4) derived 
from host cells such as macrophages, endothelial cells and neutrophils or exogenous 
stimuli derived from bacteria such as formyl-methionyl-leucyl-phenylalanine (fMLP)(34). 
The phosphatidylinositol 3-kinase (PI3K) pathway is the most important pathway 
involved  in neutrophil chemotaxis process. The role of PI3K and Rho-family GTPases in 
neutrphil polarization is illustrated in Figure 3 (43).         
 
 
 
 
14 
 
 
Figure 3. The role of PI3K and Rho-family GTPases in neutrphil polarization (modified 
from Reference 43). A) Unstimulated, resting leukocytes have a spherical shape. PI3K is 
localized in the cytoplasm and phosphatase and tensin homolog (PTEN) at the cell 
membrane. B) Binding of chemoattractant to GPCRs on leukocyte cell surface stimulates 
the production of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) by activation of PI3K 
in the membrane closest to the chemoattractant source. The external chemoattractant 
gradient is magnified inside the cell by upregulation of PIP3 production at the leading 
edge and by PIP3 dephosphorylation by PTEN at the rear of the cell. The localized 
accumulation of PIP3 promotes activation of Rho-family GTPase Rac at the leading edge. 
Subsequently, active Rac catalyzes remodeling of actin cytoskeleton, enhancing cell 
protrusions and formation of lamellipodia or filopodia at the leading edge. At the rear of 
the cell, RhoA activation catalyzes remodeling of actinomyosin cytoskeleton which 
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enhances uropod contraction. Furthermore, RhoA activation promotes PTEN activation 
at back of the cell which enhances dephosphorylation of PIP3 and this will lead to 
asymmetrical distribution of PIP3 at cell fronts, this allows stabilization of cell polarity 
and enables the cell orientation toward chemoattractant  source (43). 
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2.2 Chemokines in leukocyte recruitment   
Chemokines are chemotactic cytokines that mediate leukocytes chemotaxis in 
inflammation and in immunological responses.  They are small proteins with a molecular 
weight between 8kd to 14kd (44-46). There are about 50 chemokines in humans (with 
70% homology in amino acid sequence) which are  classified into four subfamilies 
depending on the number and position of the first two N-terminal cysteine residues in 
their structure (47,48). These four subfamilies include C, CC, CXC, CX3C. The C subfamily 
contain one cysteine residue at N-terminal side while the CC subfamily has two adjacent 
N-terminal cysteine residues. In the CXC and CX3C subfamilies, the first two N-terminal 
cysteine residues are separated by amino acids, one amino acid in CXC group and three 
amino acid in CX3C group (49,50). Chemokines are produced by various types of cells 
during inflammation such as leukocytes, endothelial cells, macrophages and fibroblasts. 
Chemokines are able to conduct the signals to their target cells through their ability to 
bind to and stimulate their seven-transmembrane GPCRs (8,51-53). The chemokine 
receptors are also categorized into four groups which are CR, CCR, CXCR and CX3CR  
similar to their corresponding chemokine subfamilies. Chemokine receptors are 
expressed by  leukocytes, neurons, endothelial cells and epithelial cells (49). 
Chemokines plays a crucial role in neutrophil migration to the site of inflammation by 
creating a concentration gradient that directs neutrophils and by activating adhesion 
molecules on neutrophil surface (8). The produced chemokines in the site of 
inflammation are immobilized on the luminal  surface of endothelium through their 
ability to bind to glycosaminoglycans (GAGs) and other molecules on endothelial surface 
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such as selectin ligands and integrin ligands (8). Subsequently, the immobilization of 
chemokines on endothelial surface enhances neutrophil recruitment and by triggering 
the rolling neutrophils to adhere firmly to the endothelium while the soluble 
chemokines are unable to induce neutrophil adhesion but can induce transendothelial 
migration by establishing chemokine concentration gradient surrounding the stimulus 
(8). It has been reported that the immobilized chemokine on endothelial cells binds to 
its receptor on neutrophil surface and activates  the integrins on the surface of 
neutrophils allowing them to bind to their ligands on endothelial surface (48). This 
interaction leads to a switch from selectin-mediated  neutrophil rolling to integrin-
mediated neutrophil firm adhesion (48). Chemokines increase the adhesion of 
neutrophils by activation of integrins via two different mechanisms, the first, 
chemokines induce rapid and transient high affinity binding of integrins to their 
endothelial ligands and the second, chemokines increase the avidity of integrins for 
their ligands (44,8).  
3. Neutrophils in inflammation          
Neutrophils are a type of polymorphonuclear leukocytes which have a major role in 
acute inflammation. They are the first leukocytes that are recruited to the inflammation 
site to eliminate pathogens. In human, neutrophils have a short half life in the 
circulation about eight to ten hours. Human neutrophils constitute 50-70% of circulating 
leukocytes and also constitute 95% of circulating granulocytes. They are produced 
continuously from the bone marrow. In the blood, mature neutrophils are spherical cells 
18 
 
with approximately 7µm in diameter. They have a segmented nucleus and their 
cytoplasm contains various types of granules (7). Neutrophils have three different types 
of granules which contain pro-inflammatory proteins. Azurophilic granules also called 
primary granules are rich in myeloperoxidase (MPO), specific granules known as 
secondary granules are filled with  lactoferrin, and gelatinase granules also named as 
tertiary granules are rich in matrix metalloproteinase 9 (MMP9). Neutrophils also have 
secretory vesicles  which are mobile vesicles, therefore, they have the ability to carry 
their contents and to incorporate them into plasma membrane surface. During 
activation of neutrophils, the secretory vesicles carry β2 integrins to neutrophil surface 
which enhance neutrophil adhesion to endothelium while gelatinase granules carry 
proteases which disrupts vascular basement membrane and extracellular matrix thus 
facilitating neutrophil emigration (7,54).           
Neutrophils are the first immunological protection line against pathogens in acute 
inflammation. They are able to synthetize and secrete pro-inflammatory cytokines such 
as TNFα and IL-1β, chemokines for example IL-8 and macrophage inflammatory protein-
1α (MIP-1α), and other inflammatory mediators such as leukotrienes and prostaglandins 
(55). These inflammatory mediators produced by neutrophils play an important role in 
the pathogenesis of acute inflammation and in elimination of invading pathogens. 
Normal body neutrophils are essential for healthy life as they maintain balanced innate 
immunity. Individuals become extremely susceptible to bacterial infection if they have 
neutrophil disorders such as neutropenia or leukocyte adhesion deficiency (LAD). On the 
19 
 
other side, hyperactive neutrophils also cause several pathologies such as vasculitis and 
glomerulonephritis (56). 
4. Mitogen- and stress-activated protein kinase-1 (MSK1)  
 4.1 MSK structure, tissue expression and activation     
Mitogen-activated protein kinases (MAPKs) constitute a vital network of signaling 
pathways that are involved in various biological functions in cells such as survival, 
proliferation, apoptosis, differentiation and neuronal and immunological functions 
(38,57,58). Abnormal MAPK cascade causes several pathologies such as autoimmune 
disorders, cancer and neurodegeneration. There are fourteen MAPKs in mammalian and 
they are classified into seven groups. Classical MAPKs include p38 isoforms (α, β, ү and 
δ), extracellular signal-regulated kinases 1/2 (ERK1/2), ERK5 and c-Jun amino (N)-
terminal kinases 1/2/3 (JNK1/2/3) while the atypical or non-classical MAPKs consists of 
ERK3/4, ERK7, and nemo-like kinase (NLK) (59-61).    
The mitogen- and stress-activated kinases 1 and 2 (MSK1, MSK2) are two kinases with 
high structural similarity and they are downstream kinases of p38 and ERK1/2 MAPKs. 
MSK1 and MSK2 consist of two kinase domains which are N-terminal domain and C-
terminal domain. The  N-terminal kinase domain belongs to the protein kinase A, G, and 
C families (AGC kinases) while the C-terminal kinase domain belongs to the calmodulin 
kinases (CAMK) (38) (Fig.4). The upstream MAPKs (p38 and ERK1/2) activate MSKs via 
phosphorylation process which occurs on at least three sites. This phosphorylation leads 
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to the activation of the C-terminal domain which results in autophosphorylation of MSKs 
and thereby activation of the N-terminal domain. Once N-terminal domain is activated, 
it acts on phosphorylation of MSK  target substrates. The sites which are phosphorylated 
on MSK by p38 MAPK are the same sites which are phosphorylated by ERK1/2 MAPK. 
The effects of activation of the ERK1/2-MSK and p38α-MSK signaling pathways on the 
cell functions may be various,  depending on different stimuli and different cell types 
used (38,62-64).   
The interaction of  ERK1/2 and p38 MAPKs with MSKs occurs at specific binding site on 
MSKs  which is called MAPK-binding domain. This MAPK binding site is located close to  
the C-terminal end of the MSKs.  Human MSK1 and MSK2 are 63% identical to each 
other. MSK1 and MSK2 also have a functional nuclear localization signal (NLS) at their C- 
terminal end. Presence of NLS segment in MSKs  makes them exclusively localized intra-
nuclearly in both quiescent and stimulated states of the cell. In accordance with this 
localization, MSK1 and MSK2 have been found to influence and modulate the nuclear 
events mainly (59). 
Analytical studies about the expression of MSKs in various tissues demonstrated that 
MSK 1 and MSK2 have ubiquitous expression, and they are predominantly expressed in 
brain, skeletal muscles, heart and placenta (59). Moreover, it has been reported that 
MSK1 was expressed in human endothelial cells and human neutrophils  (102, 113). 
Figure 4 illustrates domain structure of MSKs.     
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Figure 4. The schematic presentation of the MSK1 and MSK2 structures. MSK1 and 
MSK2 consist of two different kinase domains: the NTKD is a member of the AGC kinases 
while CTKD belongs to the CAMK kinases. The composition of the amino acids and the 
number of phosphorylation sites in both  MSK1 and MSK2  are refered to the human 
nomenclature. NLS, nuclear localization signal; D, D domain or MAPK docking site; NTKD, 
N-terminal kinase domain; CTKD, C-terminal kinase domain (modified from Reference 
59). 
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4.2 Physiological roles of MSK    
4.2.1 Regulation of gene transcription        
MSKs phosphorylate the transcriptional factor cAMP-response element-binding protein 
(CREB) in response to the mitogen and or stress-induced activation of its two upstream 
MAPKs, ERK1/2 and p38α MAPK, in different cells, such as neurons, embryonic stem 
cells, macrophages and fibroblasts. In accordance with this, the MSK1/2 double-
knockout cells demonstrated dramatic decrease in the mitogen and or stress-induced 
transcription of immediate early (IE) genes such as c-fos and nur77 which are dependent 
on cyclic AMP-response element (CRE) (38,66,67). CREB is a subfamily of transcription 
factors which also include activating factor 1 (ATF1). Similar to CREB, phosphorylation of 
ATF1 in  response to mitogens and cellular stresses is mediated  by MSK (65).     
The nuclear factor-kappa B (NF-κB) is a transcriptional factor which regulates 
transcription in response to various stimuli. The activity of NF-κB is regulated by 
posttranslational modification. MSKs phosphorylate p65 subunit of NF-κB at Ser276 and 
this phosphorylation enhances the ability of p65 to interact with the cofactors CBP and 
p300 that results in acetylation of  histones and NF-κB bound to promoters (59,68,69). It 
has been reported that MSK1/2-knockout fibroblasts showed reduction in TNF-α- 
mediated activation of NF-κB indicating that activation of MSKs is crucial for NF-κB-
dependent transcription (59,70). 
4.2.2 Regulation of nucleosomal response  
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The MSKs act as primary mediators of the nucleosomal reponse  in order to promote 
gene relaxation and activation. Nucleosomal response includes the phosphorylation of 
histone H3 on Ser10 and of high-mobility-group nucleosomal-binding protein 1 
(HMGN1) on Ser6 which takes place during induction of  immediate early genes (59,71). 
Histone H3 is one of the components of nucleosome, and the post-translation 
modification occurs at its C-terminal. Post-translation modification includes 
phosphorylation, acetylation and methylation. It has been reported that MSKs are the 
essential kinases involved in the phosphorylation process of histone H3 downstream of 
ERK1/2 and p38α MAPK cascade activation. Consistent with this, MSKs  may regulate 
transcriptional process of some non-CRE-dependent IE-genes. Histone H3 
phosphorylation in respose to various stimuli can be completely inhibited in MSK1/2- 
knockout fibroblasts (59,72).    
MSKs also phosphorylate HMGN1 (HMG-14) which is chromatin-associated protein but 
it is not the core composition in the nucleosome structure. HMGN1 causes suppression 
of phosphorylation of  histone H3 resulting in reduction in expression of IE-genes. When 
HMGN1 is phosphorylated by MSKs, the interaction of HMGN1 with nucleosome is 
reduced and this in turn allows MSKs to phosphorylate core histone H3 (59,73,74). 
4.2.3 MSKs in immunity 
4.2.3.1 T cell development 
It has been reported that both of MAPK activation and CREB signaling are involved in T 
cell development and T cell receptor (TCR) induces  CREB phosphorylation through 
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ERK1/2 signaling pathway. TCR- and IL-2-induced CREB phosphorylation is significantly 
impaired in MSK1/2-knockout mice (38,65). However, CREB-knockout mice showed 
significant decreases in the number of embryonic T cells and impaired T cell 
development (65,109). MSKs knockout mice have normal T cell number and  
development. Furthermore, the number of T cells in spleen was slightly decreased in 
MSKs-knockout mice (65). 
4.2.3.2 Role of MSKs in different models of inflammation    
Some studies demonstrated that MSKs regulate the production of cytokines during  
immunological responses to inflammatory stimuli (65). Recently, it has been reported 
that MSK1 and MSK2  have a negative regulatory role during acute inflammation 
(75,76). The studies demonstrated that MSK1 and MSK2 play a negative regulatory role 
on toll-like receptor4 (TLR4) signaling pathway. Therefore, they reduce and limit TLR4-
mediated production of many inflammatory cytokines such as IL-6, IL-12 and TNF-α. 
Moreover, it has been shown that MSK1 and MSK2 achieve this negative regulatory 
effect via their ability to induce both of the anti-inflammatory cytokines IL-10 and IL-1 
receptor antagonist (IL-1ra) and the MAPK phosphatase dual specificity phosphatase-1 
(DUSP-1)(75,76). IL-10 is an anti-inflammatory cytokine which suppresses the 
production of  proinflammatory cytokines and induces the production of the anti-
inflammatory cytokine IL-1ra by macrophages (76-78). IL-1ra is a naturally occurring 
inhibitor of IL-1 function, it has similar structure to IL-1 (homology), and thereby it binds 
to IL-1 receptor but without activating it (77). Furthermore, some studies revealed that 
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DUSP1 was able to inhibit the p38 MAPK leading to reduction in the level of  numerous 
proinflammatory cytokines such as IL-6, IL-12 and TNF-α (75,79). These results reveal 
that although ERK1/2 and p38 MAPK have a fundamental role in inflammatory process 
pathogenesis, they also induce the activation of negative feedback systems that are 
important in suppression of inflammation. The presence of hyper-activated 
proinflammatory signals causes many chronic inflammatory diseases. Therefore, the 
negative feedback systems which were reported to regulate inflammation are extremely 
important in damping the inflammatory process. Recent studies reported that both 
MSK1/2 and p38α are involved in coordination and regulation of anti-inflammatory 
reactions and  responses (75,80).  
Bertelsen et al. studied the role of MSK1 and MSK2 in chronic skin inflammation, and  
they used an oxazolone to induce allergic contact dermatitis in wild-type mice and 
MSK1/2-deficient mice (75). Their results revealed that there was a significant increase 
in inflammation in MSK1/2-deficient mice in comparison to wild-type mice. This was 
evaluated by an increase in ear thickness and in skin neutrophil infiltration. Moreover, 
they discovered that there was a significant elevation in the levels of the 
proinflammatory cytokines IL-1β and IL-6 and TNF-α at mRNA level as well as at  protein 
level in MSK1/2-deficient mice in comparison to wild-type mice. Their findings 
demonstrated that the negative feedback systems that supress skin inflammation 
induced by oxazolone were activated by MSK1 and MSK2, and that is why in MSK1/2-
deficient mice, there was a dramatic increase in inflammation over wild-type mice (75). 
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Ananieva et al. reported that animals with MSK1/2-knockout are extremely sensitive to 
endotoxic shock induced by LPS, and they also reported that the inflammation in 
MSK1/2-knockout animals continued for much longer time period than that of wild-type 
animals  in a model of toxic contact eczema (76). This study explained that the 
deficiency in MSK1 and MSK2 caused a reduction in the expression of DUSP1  and IL-10 
which are physiologically participated in the negative feedback systems that inhibit the 
immune response (59). The  study presented by Adam D. Bachstetter et al. showed the 
role of MSKs in reducing proinflammatory cytokine production, thereby reducing 
neuronal damage and degeneration (81).  
In contrast, Funding et al.  demonstrated that high level of activated MSK1 and MSK2 in 
psoriatic skin lesion compared with normal non-affected skin which indicates that MSK1 
and MSK2 play an important role in pathogenesis of psoriasis and they can be the 
therapeutic target of psoriasis (82,83). While L. Reber reported that MSK1 is involved in 
pathogenesis of murine asthma through the activation of NF-κB which enhances over-
expression of mast cell growth factor called stem cell factor (SCF) in inflammation (84).  
Therefore, MSK1 can be valuable therapeutic target to reverse mast cell related 
inflammation especially in conditions such as asthma (84).  
Furthermore, Kawaguchi et al. reported that IL-17F is involved in pathogenesis of 
asthma through induction of IL-11 over-expression and release in bronchial epithelial 
cells (85). IL-11 plays a crucial role in airway remodeling and inflammation in patients 
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with asthma. They found that ERK1/2-MSK1-CREB is a novel and important signaling 
pathway mediating IL17-F-induced asthma (85). 
The study reported by Song et al. demonstrated that ERK/p38-MSK1-CREB is the major 
signaling pathway that is involved in IL-1β- and TNF-α-induced mucin hyper-secretion in 
human airway epithelial cells during inflammation (86). 
According to all previously mentioned studies, the biological role of MSKs in 
inflammation may be heterogenous depending on tissue type, stimulus type and type of 
inflammation model used. However, the role of MSK1 in neutrophil recruitment remains 
elusive.     
 
4.3 MSK inhibitors   
Many compounds have been shown to inhibit MSKs in vivo. H89 and RO-31-8220 were 
the first inhibitors found to block MSK activity. However, neither compound is very 
specific for MSKs (65,110). In addition to MSKs inhibition, H89 was able to inhibit other 
kinases such as protein kinase A (PKA), protein kinase B (PKB), ribosomal protein S6 
kinase (RSK) and others (65,111). RO-31-8220 was originally developed as a protein 
kinase C (PKC) inhibitor, and it was subsequently found to inhibit MSK1, RSK and 
glycogen synthase kinase-3 (GSK3) with a similar potency to PKC (65,112). While both 
these compounds have been used to study MSK in cells, care must be taken in the 
interpretation of the results for two reasons.  Both  inhibitors also target other kinases, 
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including RSK, and both have also been shown in some, but not all, circumstances to 
inhibit the activation of the ERK1/2   cascade (65). Both MEK1/2 and p38 inhibitors can 
be used to block MSK activation, but both have to be used to block both MAPK 
pathways at the same time to completely inhibit MSK activation (59). Figure 5 
demonstrates the stimuli and MAPK pathways that activate MSK and the 
pharmacological inhibitors of MAPK modules used to inhibit MSK (88).    
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Figure 5. Stimuli and MAPK pathways that activate MSK. The three sequential 
organization of the MAPK cascade module is indicated to the left. Selective 
pharmacological inhibitors of MAPK module components that have been used to dissect 
MSK upstream signaling are shown in italics (modified from Reference 88). 
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Bamford et al. have reported the synthesis of a group of novel compounds of 
imidazo(4,5-c)pyridines that were able to inhibit MSK1, and the synthesis of these 
compounds resulted in inhibitors with selectivity for MSK over GSK3 and RSK in vitro 
(65,103). One of these newly discovered inhibitors is SB-747651A which has become 
available in the market  from the beginning of 2013. SB-747651A is an imidazo(4,5-
c)pyridine derivative with improved selectivity for MSK over H89 and Ro-31-8220 and 
therefore represents a useful tool to study MSK function in cells (87). In cells, it fully 
inhibits MSK activity at 5-10 µM (87). SB-747651A was found to inhibit the production of 
the anti-inflammatory cytokines IL-10 in wild-type, but not in MSK1/2-knockout, 
macrophages following LPS stimulation. Both SB-747651A treatment and MSK1/2-
knockout resulted in elevated production of pro-inflammatory cytokines by LPS-
stimulated macrophages (87). SB-747651A is a potent ATP-competitive inhibitor of 
MSK1 in vitro and it inhibits the activity of the N-terminal kinase domain of MSK1. SB-
747651A also inhibits other kinases such as PKA, PKB and RSK but despite these off-
target activities, SB-747651A provides a significant improvement over the previous 
alternatives. Both H89 and Ro-318220 have been used as MSK inhibitors, but SB-
747651A shows a better selectivity profile for MSK1 compared with these two previous 
alternatives. Thus, it is a very useful tool to study MSK function in cells (87,104).      
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Rationale for the present study 
The kinase MSK1 has been shown in various studies to play either pro- or anti-
inflammatory role in various animal models. However, there are no reports in the 
current literature showing the effect of its pharmacological suppression on leukocyte-
endothelial cell interactions in vivo. Based on the above, the following working 
hypothesis has been formulated.   
Hypothesis 
The hypothesis for this study is that pharmacological suppression of MSK1 by the 
specific inhibitor, SB747651A, modulates inflammation and leukocyte-endothelial cell 
interactions by affecting multiple steps of MIP-2-induced neutrophil recruitment in vivo.    
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Experimental objectives 
To test the above hypothesis, the following specific experimental objectives have been 
put forward : 
1. To identify the effect of MSK1 inhibition by SB747651A on MIP-2-induced 
neutrophil rolling, adhesion and emigration in vivo. 
2. To identify the effect of MSK1 inhibition by SB747651A on MIP-2-induced 
neutrophil intraluminal crawling, transendothelial migration and chemotaxis in 
cremasteric muscle tissue in vivo.                                                                                            
To achieve the above two objectives, mouse cremasteric muscle preparation and 
intravital microscopy were used to identify the effect of MSK1 inhibition by 
SB747651A on MIP-2-induced neutrophil recruitment parameters in cremasteric 
post-capillary venules and tissue.                                                                                                                                 
3. To identify the cell specific effect of MSK1 inhibition by SB747651A on 
neutrophils and  endothelial cells during MIP-2-induced neutrophil recruitment. 
Isolated primary murine neutrophils and cultured murine microvascular SVEC4-
10EE2 endothelial cell line cells were used to identify the effect of MSK1 
inhibition by SB747651A on the expression of neutrophil integrins (Mac-1 and 
LFA-1) and endothelial ICAM-1 respectively (in vitro).     
4. To identify if MSK1 has a role in neutrophils during MIP-2-induced neutrophil 
recruitment.  
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Isolated primary murine neutrophils were used to identify the effect of MIP-2 on 
MSK1 expression in murine neutrophils (in vitro).  
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Materials and methods  
1. Animals 
Two types of mice were used in this study: C57BL/6 and 129/SvJ mice. Male mice aged 
8-16 week-old were used in this study. All animal protocols were approved by the 
University Committee on Animal Care and Supply (UCACS) at the University of 
Saskatchewan and met the standards of the Canadian Council on Animal Care.      
2. Preparation of mouse for intravital microscopy 
A mixture of 10 mg/kg xylazine (Bayer Inc., Animal Health, Toronto, Ontario, Canada) 
and 200 mg/kg ketamine hydrochloride (Bioniche, Animal Health, Belleville, Ontario, 
Canada) were injected intra-peritoneally (i.p.) to anesthetize adult male mice. An 
incision was made on the neck to expose the left jugular vein, which was catheterized 
with a PE-10 tubing (Becton Dickinson, Canada) filled with 100 U/ml heparin saline 
(Sigma, Canada). For all protocols, the left jugular vein was cannulated to administer 
additional anesthetic or drugs when necessary (89,100).  
 
3. Preparation of cremaster muscle for intravital microscopy   
The mouse cremaster muscle preparation was used to study the behavior of leukocytes 
in the microcirculation and adjacent connective tissue. Briefly, an incision was made in 
the scrotal skin to expose the left cremaster muscle, which was then carefully dissected 
to free from the associated fascia. The cremaster muscle was then cut longitudinally 
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with a cautery. The testicle and the epididymis were separated from the underlying 
muscle and moved into the abdominal cavity. The muscle was secured along the edges 
with 4–0 suture. The exposed muscle was held flat and superfused with bicarbonate-
buffered physiological saline (131.9 NaCl, 4.7 KCl, 1.2 MgSO4, 20 NaHCO3, in mM, pH 7.4, 
37°C) and covered with a 22 × 22 mm glass coverslip on an optically clear viewing 
pedestal of a home-made cremaster muscle board. The cremasteric microvasculature 
was visualized using an intravital microscope (Nikon Canada Inc., Mississauga, ON, 
Canada) with a 20× objective lens and a 10x eyepiece. A digital colour video camera 
(DC220, Dage-MIT, USA) was used to project the images onto a monitor. The images 
were recorded with a DVD video recorder for subsequent playback real-time analysis to 
determine leukocyte rolling, adhesion and emigration and time-lapse analysis to 
observe and measure neutrophil intraluminal crawling, transendothelium migration and 
chemotaxis in tissue (89,90,99).         
Single venules (25–40 μm in diameter) were selected. The number of rolling, adherent, 
and emigrated leukocytes was determined offline during video playback analysis. Rolling 
leukocytes were defined as those cells moving at a velocity less than that of 
erythrocytes within a given vessel. The flux of rolling leukocytes was measured as the 
number of rolling leukocytes passing by a given point in the venule per minute. 
Leukocyte rolling velocity was measured for the first 20 leukocytes entering the field of 
view at the time of recording and calculated from the time required for a leukocyte to 
roll along a 100-μm length of venule. A leukocyte was considered to be adherent if it 
remained stationary for at least 30 s, and total leukocyte adhesion was quantified as the 
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number of adherent cells within a 100-μm length of venule in 5 min. Leukocyte 
emigration was defined as the number of cells in the extravascular space within a 200 x 
265-µm area (0.053mm2), adjacent to the observed venule (89,99,100).    
 
4. Induction of neutrophil recruitment in cremaster muscle 
To induce neutrophil recruitment in cremaster muscle, the CXC keratinocyte-derived 
chemokine (KC/CXCL1, 0.2 µg; Peprotech, Rocky Hill, USA) or macrophage inflammatory 
protein-2 (MIP-2/CXCL2, 0.2 µg; R&D Systems, Inc., Minneapolis, USA) in 100 µl of saline 
was injected intrascrotally (i.sc.) into C57BL/6 WT mice. The leukocyte rolling flux, rolling 
velocity, adhesion and emigration were measured in post capillary venule of cremaster 
muscle at 3.5, 4.0, and 4.5 h after KC or MIP-2 injection. 
To induce neutrophil recruitment independent of cytokines, an agarose gel containing 
MIP-2 was used. The agarose gel  was prepared by adding 10 ml of phosphate-buffered 
saline (2 × PBS) to a boiling concentrated agarose solution (4% in 10 ml of distilled 
water). A 110-μl aliquot of this solution was added into the lid of a 1.5-ml Eppendorf 
tube containing MIP-2 and mixed to achieve a final concentration of 0.5 μM. In order to 
visualize the gel on the cremaster muscle, a small amount of India ink was added to the 
preparation. After 30 min recording the images of the selected post-capillary venule, the 
superfusion was stopped and the coverslip was removed from the muscle. A 1 mm3 
piece of MIP-2 containing gel was punched out of the lid using the cut tip end of a 200-
µl pipette tip and the gel was carefully placed on the surface of the cremaster muscle in 
a preselected area 350-μm from the observed post-capillary venule. A 22 ×22 mm glass 
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coverslip was used to hold the gel in place and the tissue was superfused beneath the 
coverslip at a very slow rate (≤10 μl/min) to allow formation of a chemotactic gradient 
which is necessary to stimulate leukocyte emigration and chemotaxis. The images were 
recorded for 60 min after the addition of chemoattractant-containing gel. The number 
of rolling, adherent and emigrated neutrophils were determined as described previously 
during offline playback analysis of the recorded real-time video (89-91).   
 
 Cell tracking and analysis of neutrophil intraluminal crawling, transmigration and 
chemotaxis in cremasteric vasculature were measured by using ImageJ software (NIH, 
Bethesda, MD, USA) and the time-lapsed movie which was converted from the real-time 
video recording of the experiment  (90-92). The following recruitment parameters were 
quantified from tracking and analyzing at least 35 cells for each treatment group:  
a) Crawling distance: the total distance the neutrophil crawled from the initial site 
of adhesion to transmigration site (µm).  
b) Crawling time: the time spent by the neutrophil to crawl from the initial 
adhesion site to the transmigration site (min).  
c) Velocity of crawling: the crawling distance in the vessel lumen divided by 
crawling time (µm/min). 
d) Directional crawling index: the ratio of the crawling distance in the direction 
toward the MIP-2 gel to the total crawling distance the cell crawled in the lumen 
of the venule. 
e) Transmigration time: from the time the neutrophil started to transmigrate across 
38 
 
endothelium to the time the whole cell body was just outside the venule (min). 
f) Detachment time: from the time the neutrophil body was just outside the venule 
to the time when the cell body lost contact with the venule (min). 
g) Migration distance: the sum of the distance the neutrophil moved from the start 
point after detachment from the venule to the end point of the migration in 
tissue at 60 min of MIP-2 treatment or to the end point of the field of view (µm). 
h) Velocity of migration: migration distance in tissue divided by migration time 
(µm/min). 
i) Chemotaxis index in tissue: the ratio of total chemotaxis distance, i.e., the 
distance in the direction toward the MIP-2 gel, to the total migration distance 
the cell moved in tissue.   
 
5. Inhibition of MSK1    
The mice were treated with one of the two different inhibitors of MSK1: Ro-31-8220 and 
SB747651A.  Ro-31-8220 (Cayman Chemical, Michigan, USA) was given i.p. 1 h before 
administration of KC in a dose of 6 mg/kg based on previously reported optimal 
concentrations (93). SB747651A (Axon Medchem BV, Groningen, Netherlands) was 
superfused locally at a dose of 5 µM based on previously reported optimal 
concentration (87) and it was superfused 30 min prior to  placement of MIP-2 containing 
gel and  its superfusion remained for the whole duration of MIP-2 treatment (60 min). In 
another experiment, SB747651A compound was injected i.sc. 1 h before administration 
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of MIP-2 in a dose 3 mg/kg based on a dose-response concentrations which were done 
in our laboratory.   
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Figure 6. The intravital video microscopy system. An upright microscopy is linked to 
video camera which projects the images to a DVD recorder and a TV monitor. The 
prepared cremaster muscle was placed on the cremaster muscle board warmed with 
37°C circulating water and the muscle was superfused with 37°C-warmed bicarbonate-
buffered  saline (modified from Reference 90).        
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6. Isolation of mouse bone marrow neutrophils  
The femurs and tibias from C57BL/6 WT mice were isolated and their tips were 
dissected. After that, the bone marrow flashed with ice-cold Ca2+- and Mg2+-free 
phosphate buffered saline (PBS) solution. Percoll (GE Healthcare, Uppsala, Sweden) 
gradient (72%, 64%, and 52%) was use to isolate neutrophils by layering  the collected 
marrow on the top of these three percoll gradient layers followed by centrifugation at 
1060 × g for 30 min. After that, the collected neutrophils were washed with PBS (94). 
 
7. Flow cytometry analysis of neutrophil integrin Mac-1 and LFA-1 
expression 
The expression of Mac-1 and LFA-1 on neutrophils was measured by flow cytometry. 
After lysis of RBC, the isolated bone marrow neutrophils were incubated in the presence 
or absence of 5 µM SB747651A for 30 min at 37°C. Then, the cells were stimulated with 
30 nM CXCL2/MIP-2 and incubated for 10 min at 37°C. The neutrophil samples at 1 x 106 
/ml were washed in ice-cold PBS containing 1% bovine serum albumin (BSA). The 
neutrophils were stained with either a flouresence anti-Mac-1 antibody (anti-mouse 
CD11b FITC; clone M1/70; eBioscience, San Diego, CA) or a flouresence anti-LFA-1 
antibody (anti-mouse CD11a FITC; cloneM17/4; eBioscience)  or their respective isotype 
controls which are rat IgG2bκ FITC (eBioscience) for Mac-1 and rat IgG2aκ FITC 
(eBioscience) for LFA-1, and incubated at dark at 4°C for 30 min. Next, all samples were 
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centrifuged and washed twice with ice-cold PBS containing 1% BSA and then analysed 
using FL-1 channel of an Epics XL flow cytometer (Beckman Coulter, Miami, FL) (95).  
 
8. Culture of endothelial cell line cells      
Murine microvascular SVEC4-10EE2 endothelial cell line cells were obtained from 
American Type Culture Collection (ATCC, Manassas, VA). The cells were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM; Cellgro, Manassas, VA) which contains 
10% fetal bovine serum (FBS, Hyclone, Logan, UT) and antibiotics (100 IU/ml penicillin 
and 100 µg/ml streptomycin ) in a 5% CO2 incubator with maximum humidity at 37°C 
(96).   
 
9. Western blotting        
Following the treatment of murine endothelial cells for indicated length of time with 
100 nM MIP-2 or 5 µM SB747651A and following treatment of murine neutrophils with 
30 nM MIP-2, the cells were lysed in a lysis buffer (pH 8.0) which contains 150 mM NaCl, 
50 mM Tris, 1% nonidet P-40 and protease and phosphatase inhibitor cocktails. For 
measurement of endothelial ICAM-1 expression, the lysate was centrifuged (10,000 × g, 
4°C, 10 min) and the supernatant was collected. While for measurement of neutrophil 
MSK1 expression, the lysate was sonicated for 10 sec to get whole cell lysate. Next, the 
collected lysate of samples were mixed with 4 X sample loading buffer which contained 
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200 mM Tris-HCl, 50% glycerol, 0,04% bromophenol blue, 2% SDS and 20% β-
mercaptoethanol. Then the mixure was boiled for 5 min. After determination of protein 
concentration in cell lysate of all samples, the same amount of protein were used from 
all samples and separated on 7.5% SDS-PAGE and transferred electrically to a 
nitrocellulose membrane. The membrane was blocked with 5% non fat milk in TBS-
Tween buffer for 1.5 h at room temperature and incubated overnight at room 
temperature with the primary antibodies against MSK1 (1:200; Santa Cruz, CA), β-actin 
(1:2000; Santa Cruz, CA) and against ICAM-1 (1:1000; Abcam). After that, the membrane 
was incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at 
room temperature. Following washing extensively, the bands were detected with 
enhanced chemiluminescence reagents and with  X-ray to expose the bands on X-ray 
film (97,101).       
 
10. Statistical analysis 
Data in this study are expressed as mean ± SEM. Statistical analysis was performed using 
Student’s t test or one way ANOVA. n indicates the number of mice used per 
experiment.  Values of P < 0.05 were considered statistically significant.               
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Results  
1. Effect of Ro-31-8220 on  KC-induced neutrophil recruitment  
    1.1 Pretreatment with Ro-31-8220 increases rolling velocity significantly 
while no significant change in rolling flux 
KC/CXCL1, a murine CXC chemokine, is produced in the site of inflammation and 
selectively induces mouse neutrrophil recruitment (98). In this experiment, C57BL/6 
mice were injected i.sc. with 0.2 µg KC/CXCL1 to induce neutrophil recruitment in post 
capillary venules of cremaster muscle. The control mice group were injected i.p. with 
DMSO in 100 µl saline 1 h before KC administration at the same amount of DMSO in 
which  Ro-31-8220 was dissolved. To assess the effect of Ro-31-8220 on KC-induced 
neutrophil recruitment, another group, the Ro-31-8220 group, were injected with Ro-
31-8220  i.p. (6 mg/kg) 1 h before KC injection. Next, leukocyte rolling flux, rolling 
velocity, adhesion and emigration were determined at 3.5, 4.0 and 4.5 h after KC 
injection. Figure 7 (A and B) demonstrates that KC-decreased leukocyte rolling velocity 
was significantly reversed by the pretreatment with Ro-31-8220 at all time points 
(P<0.01) whereas there was no significant difference in leukocyte rolling flux between 
the two groups although it tends to be higher in Ro-31-8220-treated group at 3.5 h and 
4 h (P>0.05).    
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Figure 7. Effect of of Ro-31-8220 on KC-induced neutrophil rolling flux, rolling velocity, 
adhesion and emigration in cremasteric post-capillary venules of C57BL/6 WT mice. 
Control mice were injected intraperitoneally with DMSO in 100 µl saline 1 h before KC 
injection while Ro-31-8220 mice group were injected intraperitoneally with 6 mg/kg of 
Ro-31-8220 1 h before KC injection. Both groups were injected with 0.2 µg KC 
intrascrotally. Data represents mean ± SEM from three mice per group. *: P<0.05, **: 
P<0.01, ***: P<0.001, Ro-31-8220 group compared with the control group.   
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1.2 Both KC-induced neutrophil adhesion and emigration are significantly 
reduced by pretreatment with Ro-31-8220 
Regarding the effect of Ro-31-8220 on KC-induced neutrophil adhesion and emigration, 
Figure 7 (C,D,E and F) demonstrates that pretreatment with Ro-31-8220 decreased KC-
induced adhesion and emigration significantly at all time points (P<0.05, P<0.01 or 
P<0.001).  
The previous studies demonstrated that Ro-31-8220 has poor selectivity because it 
inhibits MSK1 with similar potency to PKC, RSK and GSK3 (65,87). For this reason, I used 
the more potent and selective inhibitor of MSK1, SB747651A, to study the effect of 
MSK1 inhibition on chemokine-induced neutrophil recruitment in the following 
experiments (87,104). Furthermore, it has been reported that 99% of recruited 
leukocytes in response to CXC chemokine MIP-2 were neutrophils and therefore, it is 
more potent neutrophil chemoattractant than KC chemokine (17 ). That is why, I used 
MIP-2 chemokine instead of KC chemokine to study the effect of MSK1 suppression by 
SB747651A on neutrophil recruitment.  
2. Effect of MIP-2 on MSK1 expression in murine neutrophils   
It has been reported that MSK1 was expressed in human neutrophils, and stimulation of 
human neutrophils with LPS increased MSK1 expression (113). In this study, to assess 
the effect of MIP-2 stimulation on MSK1 expression in murine neutrophils, we treated  
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the isolated murine neutrophils with 30 nM MIP-2 for 1 h. Figure 8 reveals that 
stimulation of murine neutrophils with MIP-2 caused up-regulation of MSK1 expression.   
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Figure 8. Effect of MIP-2 on MSK1 expression in murine neutrophils. Murine neutrophils 
were incubated without (Control) or with MIP-2 (30 nM) for 1 h. A: Original 
immunoblots (representative of 3 similar experiments) of MSK1 expression in the 
Control and MIP-2-treated murine neutrophils. B: Densitometric analysis of MSK1 
expression in the Control and MIP-2-treated  group of murine neutrophils. The values 
represent means ± SEM (n = 3). ***: P<0.001, indicates significant difference from the 
control neurophils without MIP-2 treatment.   
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3. Effect of MSK1 specific inhibitor SB747651A on MIP-2-induced 
neutrophil recruitment 
     3.1 Pretreatment with SB747651A restored MIP-2-reduced rolling flux 
and rolling  velocity, enhanced MIP-2-induced adhesion but impaired MIP-
2-induced emigration at earlier time points    
 To demonstrate the effect of MSK1 specific inhibitor SB747651A on different steps of 
neutrophil recruitment, a piece of 0.5 µM MIP-2-containing-agarose gel (1mm3) was 
placed on cremaster muscle surface at 350 µm distance and parallel to the selected post 
capillary venules to induce neutrophil recruitment. In the control group, the muscle was 
superfused with bicarbonate-buffered saline for 30 min prior to and for 60 min after 
placing MIP-2 gel while in SB747651A group, the muscle was superfused with 5 µM 
SB747651A compound for 30 min prior to the placement of MIP-2 gel and the 
SB747651A superfusion was remained for the duration of MIP-2 treatment (60 min). 
Figure 9 illustrates that superfusion of SB747651A (5 μM) on murine cremaster muscle 
subjected to MIP-2 gradient significantly increased rolling velocity, rolling flux and 
adhesion, but decreased emigration of neutrophils as compared to superfusion with 
normal saline without SB747651A.           
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Figure 9. Effect of SB747651A superfusion (5 µM) on MIP-2 gel (0.5 µM)-induced 
neutrophil rolling flux, rolling velocity, adhesion and emigration in cremasteric post-
capillary venules of 129/SvJ WT mice. The muscles of control mice were superfused with 
bicarbonate-buffered saline while the muscles of SB747651A mice group were 
superfused with SB747651A for 30 min prior to and for 60 min after MIP-2 gel 
placement. Data represents mean ± SEM from four mice per group. *: P<0.05, **: 
P<0.01, ***: P<0.001, SB747651A group compared with the control group.   
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3.2 Pretreatment with SB747651A reversed MIP-2-reduced velocity and 
enhanced MIP-2-induced adhesion and emigration at later time points 
To demonstrate the effect of MSK1 specific inhibitor SB747651A on neutrophil 
recruitment at later time points, in this experiment, the control group mice were 
injected i.sc. with 100 µl saline 1 h before MIP-2 injection, and after that they were 
given 0.2 µg MIP-2 i.sc. injection for 4 h while the SB747651A-treated group mice were 
injected i.sc. with SB747651A (3 mg/kg) 1 h before i.sc. injection of MIP-2 (0.2 µg, 4 h). 
In both groups, neutrophil recruitment parameters were determined at 3.5, 4.0, and 4.5 
h after MIP-2 injection. Figure 10 demonstrates that pre-treatment with SB747651A 
significantly reversed MIP-2-reduced leukocyte rolling velocity at 3.5 and 4 h after MIP-2 
treatment while there was no significant difference in rolling velocity at 4.5 h although it 
still tended to be higher in SB747651A-treated group. SB747651A pre-treatment further 
increased MIP-2-induced increased adhesion and emigration significantly at all time 
points.    
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Figure 10. Effect of of intrascotal injection of  SB747651A on MIP-2-induced neutrophil 
rolling flux, rolling velocity, adhesion and emigration in cremasteric post-capillary 
venules of C57BL/6 WT mice. The control mice were injected intrascrotally with 100 µl 
saline 1 h before MIP-2 administration while SB747651A mice group  were injected with 
3 mg/kg of SB747651A intrascrotally 1 h before MIP-2 injection. Both groups were 
injected intrascrotally with 0.2 µg of MIP-2. Data represents mean ± SEM from three 
mice per group. *: P<0.05, **: P<0.01, ***: P<0.001, SB747651A group compared with 
the control group.   
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4. Effect of MSK1 specific inhibitor SB747651A on MIP-2 gel-induced 
neutrophil intraluminal crawling, transmigration and chemotaxis in 
cremaster muscle 
I used Image J software to analyze time-lapsed video for determining neutrophil 
intraluminal crawling, transmigration and chemotaxis in microcirculation of cremaster 
muscle. The following  results demonstrated the effect of SB747651A on neutrophil 
intraluminal crawling, transmigration and chemotaxis in tissue. 
4.1 Pretreatment with SB747651A compound impaired MIP-2-induced 
neutrophil intraluminal crawling  
To  assess the effect of specific inhibitor of MSK1 on MIP-2-induced neutrophil 
intraluminal crawling, 5 µM of SB747651A was superfused for 30 min prior to and for 60 
min after placing 0.5 µM MIP-2 gel on cremaster muscle, while the control group was 
superfused with bicarbonate-buffered saline. Figure 11 demonstrates that both of 
intraluminal crawling distance and time tended to be higher by pretreatment with 
SB747651A although there was no significant difference from the control group. 
Accordingly, velocity of neutrophil intraluminal crawling is significantly reduced by the 
pretreatment with SB747651A in comparison to the treatment with MIP-2 alone in 
control group.  
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Figure 11. Effect of of SB747651A superfusion (5 µM) on MIP-2 gel (0.5 µM)-induced 
neutrophil intraluminal crawling in cremasteric post-capillary venules of 129/SvJ WT 
mice. The muscles of the control mice were superfused with bicarbonate-buffered saline 
while the muscles of SB747651A-treated mice were superfused with SB747651A for 30 
min prior to and for 60 min after MIP-2 gel placement. Data represents mean ± SEM 
from four mice per group. **: P<0.01, SB747651A-treated group compared with the 
control group.   
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 4.2 Pretreatment with SB747651A compound impaired MIP-2-induced 
neutrophil transmigration through endothelium 
Once the neutrophils stop crawling, they start transmigration through the endothelium 
to reach the extra-vascular space where it emigrates toward the chemokine gradient in 
tissue. Figure 12 reveals that both transmigration time and detachment time of 
neutrophils in response to MIP-2 gel were increased significantly by the pretreatment 
with SB747651A compound in comparison to treatment with MIP-2 alone in control 
group. These results indicate the impairment of neutrophil migration across endothelial 
layer after MSK1 is inhibited by SB747651A.   
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Figure 12. Effect of of SB747651A superfusion (5 µM) on MIP-2 gel (0.5 µM)-induced 
neutrophil transmigration time and detachment time in post-capillary venules of 
129/SvJ WT mice. The muscles of the control mice were superfused with bicarbonate- 
buffered saline while the muscles of SB747651A-treated mice were superfused with 
SB747651A for 30 min prior to and for 60 min after MIP-2 gel placement. Data 
represents mean ± SEM from four mice per group. **: P<0.01, SB747651A-treated group 
compared with the control group. 
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 4.3 Pretreatment with SB747651A compound impaired MIP-2-induced 
neutrophil migration velocity but not chemotaxis index in cremateric 
tissue 
The next step of neutrophil recruitment after neutrophil transmigration across the 
endothelium is to start its directional movement toward MIP-2 chemokine gradient and 
this event is termed chemotaxis. The results in Figure 13 demonstrate that the velocity 
of neutrophil migration in cremateric tissue adjacent to post capillary venule was 
significantly reduced by the pretreatment with SB747651A compound in comparison to 
the treatment with MIP-2 alone in control group while there was no significant 
difference in the directional parameter chemotaxis index between the two groups. 
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Figure 13. Effect of of SB747651A superfusion (5 µM) on MIP-2 gel (0.5 µM)-induced 
neutrophil migration and chemotaxis in cremasteric tissue adjacent to  post-capillary 
venules of 129/SvJ WT mice. The muscles of the control mice were superfused with 
bicarbonate-buffered saline while the muscles of SB747651A-treated mice were 
superfused with SB747651A for 30 min prior to and for 60 min after MIP-2 gel 
placement. Data represents mean ± SEM from four mice per group. **: P<0.01, 
SB747651A-treated group compared with the control group.  
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5. Effect of MSK1 specific inhibitor SB747651A on MIP-2-induced 
expression of  β2-integrins on neutrophils  
The β2-integrins Mac-1 and LFA-1 are expressed on neutrophil surface and are critical 
adhesion molecules in neutrophil recruitment during inflammation. It has been reported 
that LFA-1 is important for adhesion of neutrophils to the endothelial cells while Mac-1 
is important for neutrophil intraluminal crawling and subsequent efficient 
transmigration across endothelial layer (17). In this study, the isolated murine bone 
marrow neutrophils were treated with 30 nM MIP-2 for 10 min to induce β2-integrin 
expression. To assess the effect of MSK1 specific inhibitor SB747651A on Mac-1 and 
LFA-1 expression on neutrophil surface, these isolated neutrophils were treated with 5 
µM of SB747651A for 30 min prior to MIP-2 treatment. The following results were 
obtained.    
 5.1 SB747651A compound significantly decreased MIP-2-induced Mac-1 
expression in murine neutrophils 
Figure 14 reveals that co-treatment of murine bone marrow neutrophils with 
SB747651A and MIP-2 significantly reduced MIP-2-induced up-regulation of Mac-1 
expression as compared with MIP-2 treatment alone. 
 
 
64 
 
 
 
65 
 
 
Figure 14. Effect of SB747651A on MIP-2-induced up-regulation of neutrophil Mac-1 
expression in vitro. A. Representative original histograms of Mac-1-dependent 
fluorescence in bone marrow neutrophils in four different groups: neurophils of control 
group did not receive any treatment, MIP-2 neutrophils were treated with MIP-2 only 
(30 nM for 10 min), neutrophils of SB747651A group were treated with SB747651A only 
(5 µM for 30 min ), and the neutrophils of the last group were treated with SB747651A 
for 30 min prior to MIP-2 treatment. B. Data are means ± SEM (n = 3) of Mac-1-
dependent fluorescence expressed as geomeans in the four groups. # or *: P<0.05, **: 
P<0.01, ***: P<0.001. * indicates significant difference from the control neutrophils 
without MIP-2 stimulation and # indicates significant difference from the MIP-2 
stimulation without SB747651A pretreatment.   
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 5.2 SB747651A compound did not change MIP-2-induced LFA-1 
expression in murine neutrophils 
Figure 15 reveals that pre-treatment of murine bone marrow neutrophils with 
SB747651A  did not affect on MIP-2-induced LFA-1 expression on neutrophils.   
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Figure 15. Effect of SB747651A on MIP-2-induced neutrophil LFA-1 expression in vitro. 
A. Representative original histograms of LFA-1-dependent fluorescence in bone marrow  
neutrophils in four different groups: neurophils of control group did not receive any 
treatment, MIP-2 neutrophils were treated with MIP-2 only (30 nM for 10 min), 
neutrophils of SB747651A group were treated with SB747651A only (5 µM for 30 min ), 
and the neutrophils of the last group were treated with SB747651A for 30 min prior to 
MIP-2 treatment. B. Data are means ± SEM (n = 3) of LFA-1-dependent fluorescence 
expressed as geomeans in the four groups. *: P<0.05, * indicates significant difference 
from the control neutrophils without MIP-2 stimulation.  
69 
 
6. Effect of MSK1 specific inhibitor SB747651A on endothelial ICAM-1 
expression 
ICAM-1 is an important endothelial cell adhesion molecule which is expressed at basal 
level on the surface of resting endothelial cells. Its expression is up-regulated in acute 
inflammation and it mediates many steps of neutrophil recruitment. ICAM-1 mediates 
neutrophil adhesion to endothelium through the interaction with LFA-1 and it mediates 
neutrophil intraluminal crawling through the interaction with Mac-1 on neutrophil 
surface (7). In this study, we assessed the effect of MSK1 specific inhibitor SB747651A 
on endothelial ICAM-1 expression. The results in Figure 16 demonstrates that the 
expression of ICAM-1 in cultured murine endothelial cells  was up-regulated by the 
treatment with SB747651A alone but not by MIP-2 treatment alone. Co-treatment of 
endothelial cells with SB747651A and MIP-2 further significantly increased ICAM-1 
expression as compared with those treated with SB747651A alone or MIP-2 alone.      
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Figure 16. Effect of SB747651A on endothelial ICAM-1 expression. Four different 
treatment  groups were included: control group (blank), MIP-2  group (treated with MIP-
2, 100 nM for 4 h), SB747651A group (treated with 5 µM of SB747651A for 5 h), and the 
last group SB747651A+MIP-2 (treated with SB747651A compound 1 h prior to and 
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during 4 h MIP-2 treatment). A: Original immunoblots (representative of 3 similar 
experiments) of ICAM-1 expression in four different treatment groups of cultured 
murine endothelial cells. B: Densitometric analysis of ICAM-1 expression in four 
different treatment  groups of cultured murine endothelial cells. The values represent 
means ± SEM (n = 3). *: P<0.05,  # # or **: P<0.01. * indicates significant difference from 
the control endothelial cells without MIP-2 or SB747651A treatment and # indicates 
significant difference from the MIP-2 stimulation without SB747651A pretreatment.   
 
 
 
 
 
 
 
 
 
 
 
72 
 
Discussion   
Neutrophil recruitment to the site of inflammation is a crucial feature of acute 
inflammation (17). It is a multistep process regulated by specific signaling molecules. 
The signaling mechanisms that regulate neutrophil-endothelial cell interactions are still 
incompletely understood. p38 MAPK signaling was shown to regulate various steps of 
neutrophil migration in response to different inflammatory stimuli (91). MSK1 can be 
activated by either upstream ERK1/2 or p38 MAPK (64,65). To date, the role of MSK1 in 
neutrophil recruitment has not been characterized yet. Therefore, in this study, we 
investigated the effect of pharmacological inhibition of MSK1 by the more potent and 
selective MSK1 inhibitor SB7478651A on various steps of MIP-2-induced neutrophil 
recruitment. We used the CXC chemokine MIP-2 because previous studies reported that 
99% of recruited leukocytes in reponse to MIP-2 were neutrophils and it is more potent 
than another CXC chemokine KC (17). Because this study is focusing exclusively on 
neutrophil recruitment, the neutrophil selective CXC chemokine MIP-2 is  the best 
choice to study the effect of MSK1 suppression by SB747651A on neutrophil 
recruitment.  
At the beginning of this study, I demonstrated the effect of Ro-31-8220 on various steps 
of neutrophil recruitment. I found that in vivo treatment with Ro-31-8220 reversed KC-
reduced neutrophil rolling velocity and decreased both KC-induced adhesion and 
emigration. Actually, the results obtained from this study can not be interpreted well 
because it has been found that in addition to the inhibition of MSK1, Ro-31-8220 was 
73 
 
able to inhibit other kinases such as PKC, RSK and GSK3 with similar potency to MSK1 
(65). The kinases PKC and GSK3 are known to be involved in leukocyte recruitment (114-
116). Accordingly, the data obtained from this inhibitor, Ro-31-8220, can not be 
interpreted as to whether the inhibition was resulted from the inhibition of MSK1 or 
other kinases. Subsequently, in the following experiments, I used the more selective and 
specific inhibitor of MSK1, SB747651A, to study the effect of MSK1 on neutrophil 
recruitment. SB747651A is newly developed inhibitor which targets the N-terminal 
kinase domain of MSK1 which belongs to AGC kinases (87). It has been reported that 
SB747651A acts as potent and selective inhibitor of MSK1 and it has 300 times 
selectivity for MSK1 over RSK (103,104).    
The data of this study reveal that pharmacological inhibition of MSK1 by SB747651A 
modulates several steps of neutrophil recruitment. In vivo treatment with SB747651A 
significantly increased MIP-2-induced adhesion at all time points after MIP-2 treatment 
but the effect of SB747651A on neutrophil emigration seems to be time-dependent. 
Interestingly, I found that SB747651A impairs MIP-2-induced emigration at earlier time 
(30-60 min after MIP-2 treatment) points but enhanced MIP-2-induced emigration  at 
later time points (3.5-4.5 h after MIP-2 treatment). To better understand the effect of 
SB747651A on different steps of neutrophil recruitment, I assessed its effect on 
neutrophil intraluminal crawling in post capillary venules, transmigration through the 
endothelium and chemotaxis in tissue of cremaster muscle toward the MIP-2 
chemokine. As previously reported and now generally accepted, intraluminal crawling is 
the intermediate step that enables neutrophil transition from adhesion to emigration. In 
74 
 
other words, after firm adhesion to endothelium, neutrophils start crawling from 
adhesion site to the optimal transmigration site which is mostly through endothelial 
junctions (17). In this study, pharmacological inhibition of MSK1 by SB747651A impaired 
MIP-2-induced neutrophil intraluminal crawling because it caused significant reduction 
in velocity of crawling and there was tendency of incremental changes in crawling time 
and distance although not reaching statistical significance. Interestingly, both of 
transmigration time and detachment time of neutrophils were prolonged significantly in 
the presence SB747651A. In addition, although the directionality of neutrophil 
chemotaxis in tissue toward MIP-2 chemokine was not affected by SB747651A, the 
velocity of migration of neutrophils in cremasteric tissue was reduced significantly in the 
presence of SB747651A. The previous studies revealed that all adherent neutrophils 
crawl to reach to the optimal transmigration sites (mostly through endothelial junctions) 
and impairment of crawling blocks the adherent neutrophils from moving to the optimal 
transmigration sites and subsequently the neutrophils start to transmigrate through non 
or less optimal sites (directly through endothelial cell, transcellular route) causing the 
cells to spend much more time in transmigration and thus leading to dysfunctional 
emigration process which is characterized by decreased and delayed emigration at 
earlier time point (17). Interestingly in my study, impairment of MIP-2-induced 
intraluminal crawling in the presence of pharmacological inhibitor of MSK1, SB747651A, 
and the subsequent prolonged transmigration process which finally caused the 
reduction in the number of emigrated neutrophils at the earlier time points supported 
the previous reports regarding the effect of impaired emigration due to impaired 
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crawling. Since my data showed increased adherent neutrophils in the presence of 
SB747651A and the expected result from increased adherent neurophils would be the 
increased number of emigrated neutrophils. But in fact, my data show that the number 
of emigrated neutrophils at earlier time points (30-60 min after MIP-2 stimulation) was 
decreased in the presence of SB747651A and this decrease in number of emigrated 
neutrophils may be due to dysfunctional crawling as a result of SB747651A effect. The  
impaired crawling in the presence of SB747651A causing a dramatic decrease in 
emigration at earlier time points may be due to the reason that the adherent 
neutrophils transmigrate through non optimal sites prolonging their time in 
transmigration. Although these increased adherent neutrophils spent much more time 
in crawling and transmigration, they eventually migrate out of the venule  which was 
evident as the  increase in the number of emigrated neutrophis at later time points (3.5-
4.5 h) in my study.     
Furthermore, to demonstrate molecular mechanism through which the pharmacological 
inhibitor of MSK1, SB747651A, affects neutrophil recruitment, I studied the effect of 
SB747651A on MIP-2-induced β2-integrin expression on the surface of neutrophils. β2-
integrins include Mac-1 (CD11b/CD18, αMβ2 integrin) and LFA-1 (CD11a/CD18, αLβ2 
integrin). Handerson et al. demonstrated that LFA-1 is more important in neutrophil 
adhesion whereas Mac-1 is more fundamental in neutrophil migration, and their results 
were based on using Mac-1 blocking antibodies that caused dramatic decrease in 
neutrophil migration without affecting adhesion step (20).  Furthermore, Phillipson et al. 
reported that neutrophil adhesion to endothelium is mainly dependent on LFA-1 
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interaction with endothelial ICAM1/2 whereas intraluminal crawling is mediated 
predominantly by Mac-1 interaction with endothelial ICAM-1 (17). The previous study 
revealed that using Mac-1-deficient neutrophils or monoclonal antibody against Mac-1 
resulted in failure of crawling of majority of neutrophils in response to MIP-2 chemokine 
(17). It was less than 30% of Mac-1-deficient neutrophils that showed the ability of 
crawling and although they crawled, they took much longer time than the wild-type 
neutrophils indicating that impairment of crawling in Mac-1-deficient neutrophils (17). It 
has been demonstrated that neutrophils from wild-type mice transmigrated 
predominantly via endothelial junctions (86%) in contrast to neutrophils from Mac-1-
deficient mice, only minor portion of them (39%) migrated though the endothelial 
junction  while majority of them emigrated mostly through non junctional sites and this 
subsequently caused impairment of emigration process in Mac-1-deficient neutrophils 
as a result of loss of ability to reach to optimal junctional emigration sites  (17). It also 
has been reported that LFA-1 deficiency resulted in  few number of adherent 
neutrophils but those few adherent neutrophils were able to crawl efficiently (17). 
Conclusively, the previous studies confirmed that Mac-1 and LFA-1 have different and 
distinct roles in two sequential steps of neutrophil recruitment because neutrophil 
adhesion was mainly dependent on LFA-1 whereas intraluminal crawling was mainly 
dependent on Mac-1. The data of my study revealed that pharmacological inhibition of 
MSK1 by SB747651A suppressed MIP-2-induced up-regulation of Mac-1 expression in 
murine neutrophils but it did not affect on MIP-2-induced up-regulation of LFA-1 
expression. Since pretreatment with SB747651A caused reduction in MIP-2-induced  
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Mac-1 expression and based on the reported effect of Mac-1 deficiency on efficiency of 
intraluminal crawling and subsequent transmigration and emigration process (17), I 
conclude that the impairment of neutrophil crawling, transmigration and the 
subsequent emigration at early time frame after SB747651A treatment  in my study was 
likely due to Mac-1 suppressive effect of MSK1 specific inhibitor SB747651A. The 
reduction in Mac-1 caused inability of neutrophils to crawl to the optimal junctional 
endothelial sites for transmigration with subsequent prolonged transmigration through 
the non-optimal sites which finally caused the reduction in emigrated neutrophils at 
earlier time points, 30-60 min after MIP-2 stimulation.  
Previous studies have highlighted the role of ICAM-1 in several steps of neutrophil 
recruitment. ICAM-1, an endothelial cell adhesion molecule, is categorized under 
immunoglobulin superfamily. It is expressed constitutively at basal level on endothelial 
cells and its expression is increased in reponse to several inflammatory cytokines such 
as IL-1, TNF-α, INF-ү and LPS (105-108). ICAM-1 is one of major ligands of β2-integrins 
LFA-1 and Mac-1 which are expressed in neutrophils, therefore, ICAM-1 mediates 
leukocyte-endothelial cell interactions in inflammation (106). It is well-known that 
ICAM-1 mediates neutrophil firm adhesion through its interaction with LFA-1 and 
mediates neutrophil effecient intravascular crawling through its interaction with Mac-1 
on neutrophil surface (17). In our study, we demonstrated the positive effect of the 
pharmacological inhibitor of MSK1, SB747651A, on endothelial ICAM-1 expression. 
Although MIP-2 alone did not cause significant increase in ICAM-1 expression, we 
observed that endothelial ICAM-1 expression after MIP-2 stimulation was significantly 
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up-regulated in the prescence of MSK1 Inhibitor SB747651A. This result suggests that 
increased MIP-2-induced adhesion in the presence of SB747651A can be attributed at 
least partly to enhancing effect of SB747651A on endothelial ICAM-1 expression. 
Conclusion 
In this study, we revealed that MSK1 is expressed in murine neutrophils and its 
expression was up-regulated significantly after MIP-2 stimulation. We found that MSK1 
is one of downstream kinases that plays a role in MIP-2-induced neutrophil recruitment. 
Our study concludes that the more potent and selective pharmacological inhibitor of 
MSK1, SB747651A, enhances MIP-2 induced neutrophil adhesion likely through its 
positive effect on endothelial ICAM-1 expression but impairs intraluminal crawling, 
transmigration and subsequent emigration of neutrophils at earlier time points, and 
these effects may be mediated through the suppressive effect of SB747651A on MIP-2-
induced up-regulation of Mac-1 expression. Collectively, our study demonstrates that 
pharmacological inhibition of MSK1 by SB747651A affects multiple steps of MIP-2 
induced neutrophil recruitment in vivo.   
Significance of this study      
The current study is the first attempt to understand the role of MSK1 in leukocyte-
endothelial interactions in vivo. Although other studies have shown the participation of 
MSK1 in inflammation, its role in an acute, chemokine-induced inflammatory response 
has not been shown. Several studies have reported the role of p38 MAPK signaling in 
79 
 
inflammation but these studies have not addressed the role of the downstream 
molecule MSK1. We, here, show the significance of MSK1 in different steps of leukocyte 
recruitment by using intravital microscopy which enables us to study real-time cell 
behavior and dynamics of leukocyte recruitment. Furthermore, by using time-lapsed 
video microscopy we were able to analyze the different parameters of neutrophil 
recruitment such as intraluminal crawling, transmigration and extravascular chemotaxis 
which are not observed at real-time. The present research shall become the basis for 
future investigations on the role of MSK1 in innate immunity.  
Limitation of study 
This study for the first time identifies the role of MSK1 in different neutrophil  
recruitment steps during  neutrophil-endothelial cell interactions. Despite these merits, 
there are certain limitations which may preclude us to draw safe conclusions. We have 
based our entire conclusions on the data of using the inhibitor alone and not using  
MSK1 transgenic mice. Secondly, the inhibitor has been confirmed to be highly specific 
to MSK1 suppression in vivo. However, due to lack of extensive in vivo and in vitro 
studies on its safety and non toxicity, it does not warrant any clinical use at this stage. 
Because the leukocyte-endothelial cell interaction is a complex process and MSK1 is 
expressed in both leukocytes and endothelial cells, it is best to use chimeric mice 
generated by bone marrow transplantation to study the cell-specific effects of MSK1 in 
each cell type in the future.    
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